Bone scan boost: could Whole-Body SPECT sharpen radiation targeting for metastatic prostate cancer?

NCT ID NCT06439784

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial explores whether a whole-body bone scan (SPECT/CT) taken in the treatment position can help doctors plan stereotactic radiotherapy more precisely for prostate cancer that has spread to the bones. Thirty patients will receive the scan in addition to standard imaging, and researchers will compare radiation plans created with and without the SPECT images. The goal is to see if the SPECT-based plans are equivalent or better, potentially allowing for more accurate targeting of tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
whole-body SPECT/CT imaging using VERITON-CT CZT camera
What this could lead to
If SPECT/CT proves equivalent or superior to standard imaging, it could enable more precise radiotherapy planning and potentially better outcomes for prostate cancer patients with bone metastases.
What could go wrong
This is a small, early feasibility study with only 30 participants. The imaging technique may not translate into meaningful clinical benefits, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER WITH BONE METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Henri Becquerel

    Rouen, 76038, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.